Lumida
/MNKD
⌘K
MannKind Corp

MannKind Corp

MNKD
$3.75USD-1.06%-0.04 today

MARKET CAP

1.2B

P/E (TTM)

75.0x

FWD P/E

DAY RANGE

$4 – $4

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

MNKD remains range-bound under its descending 200-day SMA between support at 3.90–3.95 and resistance at 4.15–4.20. The medium-term bias is Bullish, reflecting a Stage 2 consolidation with a rounded base, but short-term EMAs are flat and momentum is neutral, offering no immediate timing edge. Execution should be deferred, waiting for either a pullback into the converged 9/20/50 EMA zone near support or a decisive breakout above the 200-day SMA. Structurally, the long-term trend remains Bearish until price can reclaim and hold above the 200-day SMA, which poses the primary risk to this view.

  • Revenue +43% YoY in Q2 to $109.4M; H1 +29% to $199.5M
  • Afrezza pediatric launch sees one-third of top 100 prescribers adopting
  • Net loss $19M in Q2 vs $0.7M income YoY highlights weak profitability
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$75.4M$99.8M$199.0M$285.5M$349.0M
YoY %+15.8%+32.2%+99.4%+43.5%+22.2%
P / Sales14.4x13.4x5.3x6.4x5.1x
EV / Sales19.8x18.2x7.7x7.9x7.3x
Gross Profit, Adj.$36.6M$42.3M$136.2M$208.9M$261.0M
YoY %-9.7%+15.5%+222.2%+53.4%+24.9%
Margin %48.5%42.4%68.5%73.2%74.8%
EV / Gross Profit40.9x42.9x11.2x10.8x9.8x
EBITDA, Adj.$-49.4M$-65.6M$15.1M$76.1M$58.8M
YoY %-37.7%-32.8%+123.1%+402.7%-22.6%
Margin %-65.5%-65.7%7.6%26.6%16.9%
EV / EBITDA-30.3x-27.7x101.1x29.6x43.3x
EBIT$-53.6M$-68.9M$10.6M$68.7M$46.5M
YoY %-34.3%-28.6%+115.4%+548.3%-32.2%
Margin %-71.0%-69.1%5.3%24.1%13.3%
EV / EBIT-27.9x-26.3x144.4x32.8x54.8x
Net Income$-80.9M$-87.4M$-11.9M$27.6M$5.9M
YoY %-41.4%-8.0%+86.3%+331.1%-78.7%
Net Margin-107.3%-87.6%-6.0%9.7%1.7%
EPS (GAAP)-$0.32-$0.34-$0.04$0.10$0.02
YoY %-23.1%-6.3%+88.2%+350.0%-80.0%